Uveal melanoma survival in Sweden from 1960 to 1998

被引:67
作者
Bergman, L
Seregard, S
Nilsson, B
Lundell, G
Ringborg, U
Ragnarsson-Olding, B
机构
[1] St Eriks Eye Hosp, SE-11282 Stockholm, Sweden
[2] Karolinska Hosp, Radium Hemmet, Dept Gen Oncol, S-10401 Stockholm, Sweden
关键词
D O I
10.1167/iovs.03-0081
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
PURPOSE. To investigate the crude and relative survival rates in patients with uveal melanoma in Sweden during the period from 1960 to 1998. METHODS. A population-based national survey revealed 2997 cases of uveal melanoma in the Swedish Cancer Registry. The survival rates were calculated by the Hakulinen life-table method, using relative survival as an estimate for deaths due to uveal melanoma. The excess mortality rates were calculated with confidence intervals for the first 15 years after diagnosis. Multivariate regression analysis was undertaken to evaluate the influence of gender, age, and calendar period on relative survival the first 5 years after diagnosis. The underlying causes of deaths in the patients with uveal melanoma, as found in the Cause of Death Registry were also investigated. RESULTS. Up to December 31, 1998, 2003 patients had died. The 5-year crude survival rate was 60.3% and the relative survival 70.1%. After 10 years, the rates were 42.5% and 59.4%, respectively. Significant excess mortality existed up to 5.5 years after diagnosis. In the multivariate model, younger age (P < 0.001) and later calendar period (P = 0.002), but not gender (P = 0.117), were associated with better relative survival. Deaths due to uveal melanoma were misclassified in the Cause of Death Registry in more than half of the cases. CONCLUSIONS. This study, covering more than 95% of the uveal melanoma cases in the Swedish population revealed an improvement in relative survival rates for patients with uveal melanoma over time and a significant excess mortality up to 5.5 years after diagnosis.
引用
收藏
页码:3282 / 3287
页数:6
相关论文
共 38 条
[1]   Delays in the diagnosis of uveal melanoma and effect on treatment [J].
Ah-Fat, FG ;
Damato, BE .
EYE, 1998, 12 (5) :781-782
[2]  
Albert DM, 1998, AM J OPHTHALMOL, V125, P779
[3]   Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroidal melanomas: results in patients treated between 1980 and 1987 [J].
Augsburger, JJ ;
Schneider, S ;
Freire, J ;
Brady, LW .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 1999, 237 (07) :558-567
[4]   Treatment of disseminated ocular melanoma with sequential fotemustine, interferon α, and interleukin 2 [J].
Becker, JC ;
Terheyden, P ;
Kämpgen, E ;
Wagner, S ;
Neumann, C ;
Schadendorf, D ;
Steinmann, A ;
Wittenberg, G ;
Lieb, W ;
Bröcker, EB .
BRITISH JOURNAL OF CANCER, 2002, 87 (08) :840-845
[5]  
Bergman L, 2002, INVEST OPHTH VIS SCI, V43, P2579
[6]   Ten-year follow-up of helium ion therapy for uveal melanoma [J].
Char, DH ;
Kroll, SM ;
Castro, J .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 1998, 125 (01) :81-89
[7]  
De Croock L, 2002, Bull Soc Belge Ophtalmol, P59
[8]  
Diener-West M, 2001, ARCH OPHTHALMOL-CHIC, V119, P969
[9]   A REVIEW OF MORTALITY FROM CHOROIDAL MELANOMA .2. A METAANALYSIS OF 5-YEAR MORTALITY-RATES FOLLOWING ENUCLEATION, 1966 THROUGH 1988 [J].
DIENERWEST, M ;
HAWKINS, BS ;
MARKOWITZ, JA ;
SCHACHAT, AP .
ARCHIVES OF OPHTHALMOLOGY, 1992, 110 (02) :245-250
[10]  
EDERER FRED, 1961, NATL CANCER INST MONOGR, V6, P101